NewAmsterdam Pharma Company NAMS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $22.57M+0.3% | $22.5M-36.1% | $35.24M-44.9% | $64.01M+35.8% | $47.14M+3.5% | ||
| $135.09M-4.8% | $141.83M+2.7% | $138.13M-3.3% | $142.86M-7.1% | $153.73M+1.5% | ||
| $102.65M-3.5% | $106.35M+6.3% | $100.04M+6.5% | $93.93M+13.0% | $83.15M+18.0% | ||
| $237.74M-4.2% | $248.19M+4.2% | $238.18M+0.6% | $236.8M0.0% | $236.87M+6.8% | ||
| $237.74M-4.2% | $248.19M+4.2% | $238.18M+0.6% | $236.8M0.0% | $236.87M+6.8% | ||
| -$215.18M+4.7% | -$225.68M-11.2% | -$202.93M-17.4% | -$172.79M+8.9% | -$189.73M-7.6% | ||
| -953.6%+49.3pp | -1,002.9%-427pp | -575.8%-306pp | -270%+133pp | -402.5%-15.6pp | ||
| $25.89M-6.2% | $27.59M+7.8% | $25.6M+9.7% | $23.33M+10.3% | $21.15M+25.3% | ||
| $7.23M-45.0% | $13.14M+149% | $5.27M-45.9% | $9.73M+8,513% | $113K+102% | ||
| -$212.73M-4.4% | -$203.82M+7.8% | -$221.07M-33.4% | -$165.72M+11.6% | -$187.36M+22.5% | ||
| —— | —— | —— | —— | —— | ||
| -$212.73M-4.4% | -$203.82M+7.8% | -$221.07M-33.4% | -$165.72M+11.6% | -$187.36M+22.5% | ||
| -942.8%-37.0pp | -905.7%-278pp | -627.3%-368pp | -258.9%+139pp | -397.5%+133pp | ||
| -$1.79-3.5% | -$1.73+15.6% | -$2.05-26.5% | -$1.62+13.8% | -$1.88+27.7% | ||
| -$1.79-3.5% | -$1.73+15.6% | -$2.05-26.5% | -$1.62+13.8% | -$1.88+27.7% | ||
| —— | —— | —— | —— | $24.32M-34.3% | ||
| $30.6M+34.3% | $22.78M-15.7% | $27.02M+2,001% | -$1.42M+73.8% | -$5.43M-114% | ||
| -$212.95M-4.6% | -$203.49M+7.9% | -$220.86M-33.2% | -$165.81M+11.5% | -$187.35M+22.4% | ||
| $7.23M-45.0% | $13.14M+149% | $5.27M-45.9% | $9.73M+8,513% | $113K+102% | ||
| —— | —— | —— | —— | —— | ||
| -$213K-165% | $326K+76.9% | $184.25K+257% | -$117.5K-15,767% | $750-98.3% | ||
| $22.57M+0.3% | $22.5M-36.1% | $35.24M-44.9% | $64.01M+35.8% | $47.14M+3.5% | ||
| -$215.18M+4.7% | -$225.68M-11.2% | -$202.93M-17.4% | -$172.79M+8.9% | -$189.73M-7.6% | ||
| -$214.95M+4.7% | -$225.46M-11.2% | -$202.72M-17.4% | -$172.62M+8.9% | -$189.58M-7.6% | ||
| -$214.95M+4.7% | -$225.46M-11.2% | -$202.72M-17.4% | -$172.62M+8.9% | -$189.58M-7.6% | ||
| -952.6%+49.4pp | -1,001.9%-427pp | -575.2%-306pp | -269.7%+132pp | -402.2%-15.5pp | ||
| -$215.18M+4.7% | -$225.68M-11.2% | -$202.93M-17.4% | -$172.79M+8.9% | -$189.73M-7.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's income statement data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.